Sugi Predict

Sugi Predict / Targets / SRC

SRC

Proto-oncogene tyrosine-protein kinase Src · P12931 · SRC on Sugi Atlas →

382,952 patent compounds predicted against SRC, 258,899 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Saracatinib Saracatinib (SCHEMBL41547) 1.00 18/20
SCHEMBL10811 SCHEMBL10811 0.57 18/20
SCHEMBL40869 SCHEMBL40869 0.52 18/20
SCHEMBL12162 SCHEMBL12162 0.74 17/20
SCHEMBL42089 SCHEMBL42089 0.60 16/20
SCHEMBL12351 SCHEMBL12351 0.65 14/20
SCHEMBL11807 SCHEMBL11807 0.59 14/20
SCHEMBL11310 SCHEMBL11310 0.56 14/20
SCHEMBL11442 SCHEMBL11442 0.55 14/20
SCHEMBL9010 SCHEMBL9010 0.54 14/20
SCHEMBL12366 SCHEMBL12366 0.67 13/20
SCHEMBL10508 SCHEMBL10508 0.61 13/20
SCHEMBL12282 SCHEMBL12282 0.59 13/20
SCHEMBL41155 SCHEMBL41155 0.52 13/20
SCHEMBL10691 SCHEMBL10691 0.61 12/20
SCHEMBL42350 SCHEMBL42350 0.51 12/20
SCHEMBL12315 SCHEMBL12315 0.75 11/20
SCHEMBL41605 SCHEMBL41605 0.62 11/20
SCHEMBL1255 SCHEMBL1255 0.61 11/20
SCHEMBL11313 SCHEMBL11313 0.54 11/20

Clinical trials — most relevant to SRC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
TORI 104 Pre-Surgical Dasatinib PHASE2WITHDRAWN
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma PHASE2COMPLETED
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction PHASE2COMPLETED
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery PHASE2COMPLETED
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma PHASE2COMPLETED
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer PHASE2COMPLETED
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. PHASE2COMPLETED
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer PHASE1COMPLETED
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Clinical Study to Evaluate SM17 in Healthy Participants PHASE1COMPLETED
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment PHASE1COMPLETED
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma PHASE1UNKNOWN
Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SRC binder may also engage these)

ProteinNameSimilarity
P63185 — 1.000 P63185 →
P00525 — 1.000 P00525 →
P05480 — 1.000 P05480 →
P00524 — 1.000 P00524 →
P25020 — 1.000 P25020 →
P00526 — 1.000 P00526 →
Q9WUD9 — 0.999 Q9WUD9 →
P50545 — 0.999 P50545 →
Q6EWH2 — 0.999 Q6EWH2 →
YES1 Tyrosine-protein kinase Yes 0.998 landscape →
P13116 — 0.998 P13116 →
P10936 — 0.997 P10936 →
P00523 — 0.997 P00523 →
P31693 — 0.997 P31693 →
P13115 — 0.997 P13115 →
P39688 — 0.996 P39688 →
FYN Tyrosine-protein kinase Fyn 0.996 landscape →
P14084 — 0.996 P14084 →
P14085 — 0.996 P14085 →
FGR Tyrosine-protein kinase Fgr 0.996 landscape →
Q62844 — 0.996 Q62844 →
F1RDG9 — 0.995 F1RDG9 →
Q1JPZ3 — 0.995 Q1JPZ3 →
P00527 — 0.995 P00527 →
Q28923 — 0.994 Q28923 →
A1A5H8 — 0.993 A1A5H8 →
Q02977 — 0.993 Q02977 →
P27447 — 0.993 P27447 →
F1LM93 — 0.993 F1LM93 →
P27446 — 0.993 P27446 →